- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00753948
Exhaled Levels of Nitric Oxide
The Effect of Nitric Oxide on Pulmonary Resistances and Blood Pressure in Persons With Tetraplegia
Previously it was observed that individuals with tetraplegia have reduced baseline airway caliber and exhibit non-specific airway hyperresponsiveness (AHR). In persons with tetraplegia we have suggested that this is due to overriding cholinergic airway tone. In asthma, the mechanisms underlying bronchoconstriction and AHR are more closely tied to airway inflammation. Whether AHR in tetraplegia is also related to chronic airway inflammation is unknown.
Recently, a non-invasive technique for assessing airway inflammation has been established in asthma that involves measurement of nitric oxide (NO) concentrations (FeNO) in expired air. FeNO is elevated in asthma likely due to excess NO production by inflammatory cells within the airway Measurement of FeNO in persons with tetraplegia would help in assessing the role of airway inflammation in this population. This may have therapeutic significance in such individuals. NO in the lung is felt to be the principal inhibitory neurotransmitter of the non-adrenergic, non-cholinergic (NANC) system. It is thought that inhalation of NO has no effect on airway tone in healthy individuals but reduces methacholine responsiveness while having weak direct bronchodilatory effect in asthmatics.
The primary purpose of this study is to determine the levels of exhaled NO (FeNO) in individuals with chronic cervical spinal cord injury (SCI), and to compare them with those obtained in age and sex matched able-bodied individuals and subjects with stable mild to moderate asthma. If the FeNO levels are high and comparable to those found in asthmatic subjects, this will imply the role of chronic inflammation in reduced baseline airway caliber and non-specific airway hyper-responsiveness (AHR) exhibited by individuals with chronic cervical SCI. If the FeNO levels are comparable with those found in able-bodied controls, this will support our previous statement that unopposed cholinergic innervation is responsible for low baseline airway caliber and AHR in individuals with chronic tetraplegia. Further scientific conclusions about NO and its role in control of airway tone, pulmonary resistances and blood pressure will be drawn upon intravenous and inhaled administration of L-NAME. This compound has been shown promising results for the treatment and prevention of orthostatic hypotension in individuals with tetraplegia. Knowing its effects on airways and potential of easier mode of delivery (inhalation vs. intravenous) is of utmost importance.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States, 10468
- VA Medical Center, Bronx
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent.
- Age between 18 and 65 years.
- Able-bodied individuals, persons with mild asthma or individuals with tetraplegia for at least one year of duration.
- Able to perform acceptable pulmonary function tests and follow procedures.
Exclusion Criteria:
- coronary artery disease;
- active cigarette smokers or previous smokers who stopped <5 years ago;
- MI or stroke within 3 months;
- moderate to severe reduction in lung function defined as FEV1 < 70 % predicted (except in individuals with tetraplegia);
- hypertension;
- medications known to affect the cardiovascular system;
- pregnancy
- current use of cholinesterase medication; and
- lack of mental capacity to give informed consent Group specific exclusion criteria for
Asthmatic subjects:
- Moderate to severe disease as per spirometric indices;
- testing within 48 hours of last administration of long acting inhaled bronchodilator;
- testing within 7 days of last administration of glucocorticoids;
- testing within > 24 hours since last administration of leukotriene modifiers; and
- testing within 8 hours of last administration of a short acting bronchodilator medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chronic Tetraplegia
Individuals with chronic tetraplegia
|
A non-specific inhibitor of the nitric oxide synthase enzyme.
|
Active Comparator: Mild Asthma
Individuals with diagnosed mild asthma
|
A non-specific inhibitor of the nitric oxide synthase enzyme.
|
Placebo Comparator: Healthy Control
Neurologically intact, otherwise healthy, age-matched control
|
A non-specific inhibitor of the nitric oxide synthase enzyme.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exhaled Levels of Nitric Oxide
Time Frame: Exhaled NO reported during visit, before intervention at baseline, post intervention at 60 minutes and 120 minutes
|
Nitric Oxide was measured applying a real time technique for measurement of Nitric Oxide in Exhaled Breath Condensate.
Elevated Nitric Oxide in exhalate is a measure of elevated production of NO in conditions such as underlying inflammation and/or oxidative stress.
Exhaled NO was reported as the mean of three values within 10% of each other.
|
Exhaled NO reported during visit, before intervention at baseline, post intervention at 60 minutes and 120 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specific Airway Conductance (sGaw) as Measured by Plethysmography
Time Frame: Specific airway conductance reported during visit, before intervention at baseline, post intervention at 60 minutes and 120 minutes
|
Specific airway conductance (sGaw) is the airway conductance relative to lung volume because it takes into account the important effect of lung volume on airway resistance, it is a useful index of bronchomotor tone.
|
Specific airway conductance reported during visit, before intervention at baseline, post intervention at 60 minutes and 120 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Miroslav Radulovic, MD, VA Medical Center, Bronx
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B4335-V
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on N-Nitro L-arginine-methylester (L-NAME)
-
US Department of Veterans AffairsCompletedHypotension | Spinal Cord InjuryUnited States
-
Regional Hospital HolstebroCompletedHealthy | Obstructive Sleep ApneaDenmark
-
Juliano CasonattoUnknown
-
Uppsala UniversityThe Swedish Society of Medicine; Bengt Ihre FoundationCompletedGastrointestinal Motility Disorder | Disturbance of Salivary SecretionSweden
-
Karolinska InstitutetCompletedType 2 Diabetes MellitusSweden
-
Rambam Health Care CampusUnknownAtherosclerosis | Diet Modification | Serum; Disease
-
Emory UniversityNational Center for Complementary and Integrative Health (NCCIH); Children's...CompletedSickle Cell Disease | Vaso-occlusive Pain EpisodeUnited States
-
Instituto de Oncología Ángel H. RoffoCompletedUnresectable Multiple Brain Metastases
-
Hospital Civil de GuadalajaraNot yet recruitingArginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth CurveFetal Growth Retardation
-
University Hospital, Strasbourg, FranceCompletedSkeletal Muscle Ischemia | Severe Lower Limb Ischemia | Mitochondrial DysfunctionFrance